A front page article in the New York Times today by Gina Kolata, “How Bright Promise in Cancer Testing Fell Apart”, chronicles a patient case study at Duke University about gene based tests for lung cancer. Additional commentary at other research institutions suggests that “good science has not caught up with the financial push.”

We will provide more Company analysis on Monday as this news as digested.

Diagnostic and tools stocks were generally weak but in line with NASDAQ.

Bigger losers were :Response Genetics(RGDX) down 5% , Complete Genomics  (GNOM) down 3%,and Myriad (MYGN) down 2.4%.

%d bloggers like this: